Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec 4Q

Tysabri revenues in the quarter increased 39% to $216 million and Avonex revenues were up 5% to $596 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 4Q

4Q Revenues: $1.1 billion (+5%)

4Q Earnings: $306 million (+48%)

FY Revenues: $4.4 billion (+7%)

FY Earnings: $1.0 billion (+24%)

Comments: Tysabri revenues in the quarter increased 39% to $216 million and Avonex revenues were up 5% to $596 million. Rituxan revenues in the quarter were down 15% to $257 million. Growth for the year was driven primarily by Tysabri sales, which increased 32% to $776 million, and Avonex sales, which increased 5% to $2.3 billion. Rituxan revenues from the company’s joint business arrangement decreased 3% to $1.1 billion for the year due to the expiration of royalties on sales outside the U.S. Revenues from other products in the quarter were $14 million, compared to $10 million in 4Q08, and for the year were $54 million, compared to $49 million FY08.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters